Get started

TTOO

T2 Biosystems - 3.90 or 1.00 ? Preliminary unaudited fourth quarter 2020 total revenue is expected to be $7.8 million, including product revenue of $5.8 million, representing growth of 155% and 274% respectively, compared to the prior year period Preliminary unaudited full year 2020 total revenue is expected to be $18.1 million, including product revenue of $11.7 million, representing growth of 118% and 119% respectively, compared to the prior year period The company is making progress but they’re still not hitting their own goals ! TTOO has 50% fibo touch retracement. If it breaks the support, then the price will reach 1.74 ; Price 2.50 is a monthly strong support / resistance ! If it breaks the resistance , then the price will reach 3.90 ; LONG in the next 12 months Trigger: Waiting for a momentum candle close below the gray area to buy. Good luck!
NASDAQ:TTOOLong
by premieranalysis
TTOO - Federal Contract Creating Hype. Above The TrendT2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA. SHORT INTEREST 5.5M 08/30/19 P/E Current -2.07 P/E Ratio (with extraordinary items) -2.04 Average Recommendation: OVERWEIGHT Average Target Price: 3.71
NASDAQ:TTOOLong
by DEXWireNews